DSIJ Mindshare

Promoters and FIIs increased stake: This small-cap pharma company targeted Rs 750 crore revenue!

The company plans to launch several new products in the domestic and export markets in Q3 and Q4 of FY24.

Aniket Gogate 0 1484 Article rating: 5.0

FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.

Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.

This Smallcap speciality chemical stock announces 1:5 stock split!

The company continues to improve its working capital efficiency resulting in reduction in inventory and debtor days.   

Karan Dsij 1 4473 Article rating: 4.1

In Q2FY23, the company continues to report record quarterly sales, EBITDA and PAT. Consolidated domestic and exports sales continued its growth trend, growing by 57 per cent and 53 per cent YoY.

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR